CSI Market
Sign In | Register

Calidi Biotherapeutics Inc (CLDI) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CLDI Annual Cash Flow →
From Calidi Biotherapeutics Inc through Jun 30 2025, changes in Jun 30 2026's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-16.85
Depreciation & amortization1.06
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.39
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Marketable Securities Unrealized Gain Loss-
Gain Loss Due To Change In Fair Value Of Forward Purchase Units-
Allocation Of Deferred Offering Costs For Warrant Liability-
Operating Lease Right Of Use Asset Amortization Expense-
Changes In Fair Value Of Debt And Other Liabilities-
Preferred Stock Financing Costs-
Gain Loss Related To Litigation Settlement-
Increase Decrease In Operating Lease Liability-0.33
Change In Fair Value Of Other Liabilities And Derivatives-0.05
Income taxes0.00
Gain on Sale of Investments0.00
Accounts Receivable-0.02
Increase (Decrease) in Accounts Payable0.31
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-0.73
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.33
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities7.04
Discontinued operations0.00
Net Cash flow from Operating Activities-8.47
Investing Activities
Capital Expenditures-0.04
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payment Of Extension Fee-
Withdrawal For Redemption Payment-
Cash Assumed In Connection With The F L A G Merger-
Proceeds From Payments For Security Deposits-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.04
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.29
Long-term debt - borrowings0.00
Long-term debt - repayments-0.09
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net5.37
Proceeds From The Issuance Of Temporary Equity-
Proceeds From Non Redemption P I P E Subscription Agreement-
Proceeds From Simple Agreements For Future Equity-
Repayment Of Principal On Related Party Term Notes Payable-
Repayment Of Principal On Term Notes Payable-
Proceeds From May Inducement Offer-
Repayment Of Convertible Note Payable-
Payment Of Debt Issuance Costs-
Proceeds From Issuance Of Noncontrolling Interest-
Proceeds From Issuance Of Common Shares And Warrants Per Subscription Agreement-
Proceeds From Issuance Of Series B Preferred Stock-
Proceeds From April Public Offering-
Proceeds From Registered Direct Offering-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities6.99
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-8.51
Total Cash Flow-1.53
4 historic quarters locked

Sign in to unlock the full Calidi Biotherapeutics Inc cash flow history.

Sign In Create Free Account

About Calidi Biotherapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 13, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-037847

Figures are derived from filed reports and may be restated. Historical data is subject to revision.